Biofrontera Inc.
BFRIDrugs in Pipeline
4
Phase 3 Programs
3
Upcoming Catalysts
1
Next Catalyst
Next month
Market Overview
Stock performance and key metrics
1 upcoming, 0 past
BF-200 ALA gel
Actinic Keratosis
BF-200 ALA
Actinic Keratosis
methyl-aminolevulinate
Basal Cell Carcinoma (BCC)
BF-200 ALA 1%
Actinic Keratosis
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
BF-200 ALA gel | Phase 3 | Actinic Keratosis | - | - |
BF-200 ALA | Phase 3 | Actinic Keratosis | - | - |
methyl-aminolevulinate | Phase 3 | Basal Cell Carcinoma (BCC) | - | - |
BF-200 ALA 1% | Phase 2 | Actinic Keratosis | - | - |
Full breakdown — the signals behind the verdict
Frequently asked questions
What is in Biofrontera Inc.'s drug pipeline?→
CatalystAlert tracks 4 drug candidates in Biofrontera Inc.'s (BFRI) pipeline across Phase 3, Phase 2. Its lead program is BF-200 ALA gel (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Biofrontera Inc.'s next FDA catalyst?→
Biofrontera Inc.'s (BFRI) next tracked catalyst is a Earnings expected November 11, 2026. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track BFRI biotech catalysts?→
Add BFRI to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Biofrontera Inc.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.